WILSON TROY EDWARD purchased $1.5M of KURA

WILSON TROY EDWARD (President and CEO) purchased 200,000 shares of Kura Oncology, Inc. (KURA) at an average of $7.52 ($7.42–$7.63, $1.50M total) across 2 trades over 2026-11-13 to 2026-11-16.

Original reporting
SEC EDGAR · WILSON TROY EDWARD
Published Nov 17, 2026, 12:45 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 17, 2026, 12:51 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$KURA
Bullish
medium confidence
Mentioned
$KURA
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$KURABullishLow
01

Why it matters

This provides a fresh, primary datapoint on executive share accumulation, but it does not include new clinical, regulatory, financial, or strategic information that would typically drive repricing.

02

Market read

Traders may treat the filing as a small sentiment input, but it is unlikely to be a standalone driver of price without accompanying company catalysts.

03

What to watch

The article notes no pre-arranged 10b5-1 plan, but it does not provide intent, option exercises, or whether the CEO has ongoing buying patterns.

Relevance 7/10Novelty 6/10Timing: SEC Form 4 filed 2026-11-16, covering purchases from 2026-11-13 to 2026-11-16.

Background

The article is an SEC Form 4 insider transaction disclosure for Kura Oncology, Inc. (KURA).

Company-level read

Ticker impact

$KURABullishMedium confidence
Context

CEO and President Wilson Troy Edward bought 200,000 shares of Kura Oncology in open-market trades totaling about $1.50M, per Form 4.

Expected impact

Likely limited near-term impact, with any reaction fading unless accompanied by additional company-specific news.

Evidence & confidence

The filing is a primary SEC Form 4 disclosure and the buyer is a top executive, but the transaction is an insider purchase without new operational or guidance information.

Market effects

Minimal, as this is a single-company insider transaction with no disclosed sector-wide development.

None.

None.

Counterpoint

Insider purchases can be routine or driven by liquidity planning, diversification, or pre-existing trading arrangements, so the signal may be overstated.

Key entities

  • Kura Oncology, Inc.

    Biopharmaceutical company subject of the insider Form 4 disclosure.

  • Wilson Troy Edward

    President and CEO who purchased shares in open-market transactions.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$KURAMed

Kura Oncology Q3 Earnings Call Highlights

Kura Oncology (KURA) reported Q3 net loss of $70.2M, down 5% YoY. The company presented plans for ziftomenib, including combination studies and frontline trials, with top-line results expected in 2028. Kura also announced plans for darlifarnib studies and a financing agreement with Oberland Capital. Cash reserves stood at $492M, with guidance for 2026-2028 collaboration revenue.

$KURAMed

Kura Oncology Reports THIRD Quarter 2026 Financial Results AND CORPORATE UPDATE

Kura Oncology, Inc. (KURA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Kura Oncology Reports THIRD Quarter 2026 Financial Results AND CORPORATE UPDATE – KOMZIFTI ® (ziftomenib) net product revenue grew 53% sequentially to $13.9 million; new patient starts increased 30% and total prescriptions grew 65% – – KOMZIFTI maintained majority sh

$KURAMedAI 8/10

A leukemia drug’s first results with two other medicines will be presented in December.

Kura Oncology (KURA) and Kyowa Kirin (4151) will present data on ziftomenib, their leukemia drug, at the 2026 ASH Annual Meeting. Key presentations include combination results with quizartinib and gilteritinib, longer-term data with venetoclax and azacitidine, and exploratory analysis in additional AML subtypes. The companies aim to establish ziftomenib as a preferred menin inhibitor for combination treatments. An investor webcast is scheduled for December 15, 2026.